Yarrow Bioscience Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeNASDAQ

Market Capitalization182.37 mln

Float8.41 mln

Earnings Date11/05/2026

Piotroski F-Score

6 / 9

Solid

Beneish M-Score

-3.23

Reliable

Relative Strength

46 / 100

Slightly lagging

Pre-Tax Margin

-3,914%

Severely loss-making

ROE

-64.32

Deeply negative

Dividend Yield

103%

Risk of cut

Business Description

Yarrow Bioscience Inc. is a New York-based biotechnology company founded in 2025, focused on creating new treatments for autoimmune thyroid conditions. Its lead drug candidate, YB-101, is a humanized monoclonal antibody designed to target the thyroid-stimulating hormone receptor, with the goal of treating Graves' disease and thyroid eye disease.

Key Fundamentals

EPS-23.46

ROE-64.32

RPS0.56

ROIC-2,826

ROA-58.29

EBITDA, mln-18.84

EV / EBITDA-10.08

EV / EBIT-10.07

Revenue, mln0.48

EV / Revenue394

Quote Details

Last 19.27

Change -0.33 (-1.68%)

Open 19.96

Volume 146,390

Turnover 2,820,935

Average Volume 127,738

Financial Ratios

Pre-Tax Profit Margin-3,914

Leverage Ratio1.07

Current Ratio15.26

Price / Book0.66

Price / Tangible Book0.66

Price / Sales36.14

Financial Strength

Altman Z-Score42

Piotroski F-Score 6 / 9

Beneish M-Score-3.23

Short Ratio1.15

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	5.24%	89 / 100
1 Month	-26.08%	14 / 100